Producer
Unither Pharmaceuticals
Leading CDMO for blow-fill-seal sterile unit-dose (eye drops, nebules, oral liquids); BFS contract manufacturing at scale.
1
Inputs supplied
1
Goods downstream
0
Facilities
0
Stories
What they make
1 input Unither Pharmaceuticals supplies
Click an input to see every good that depends on it, every country that produces it, and every other company in the supply chain.
Where it shows up
Goods downstream
Essential goods that depend on something Unither Pharmaceuticals makes, pick one to see the full supply chain.
What else they do
Business segments
The company's full revenue map, where this supply-chain role fits within their broader business.
BFS Ophthalmic Unit-Dose Manufacturing
42%BFS Respiratory & Nebulizer Unit-Dose Manufacturing
31%BFS Oral & Nasal Unit-Dose Manufacturing
18%Pharmaceutical Development Services
9%
Intelligence
What's known
Sourced claims about this company's role in supply chains, chokepoints, concentration, incidents, dual-use connections.
Did you know2024
Unither Pharmaceuticals manufactures unit-dose BFS ampoules for three entirely different pharmaceutical supply chains simultaneously on the same production equipment at their French facilities: (1) branded OTC dry-eye products (Systane, Refresh Tears, and generic artificial tear drops) used daily by tens of millions of dry-eye patients; (2) albuterol/salbutamol nebulizer ampoules dispensed by emergency departments and used by asthma and COPD patients during acute exacerbations; and (3) 0.9% sodium chloride saline ampoules used in NICUs for neonatal nasal irrigation and in hospital wards for IV line priming and wound irrigation. A single production disruption at Unither's Amiens facility would simultaneously affect consumer ophthalmic, emergency respiratory, and neonatal hospital supply chains — three critical-but-unconnected pharmaceutical market segments sharing the same contract manufacturer without most buyers knowing it.
Unither Pharmaceuticals ↗Concentration2024
Most major pharmaceutical brands selling unit-dose eye drops, nebulizer ampoules, or saline vials do not manufacture these products themselves — they are contract-manufactured by a small number of BFS CDMOs globally, primarily Nephron Pharmaceuticals (US), Catalent, Unither, and a handful of in-house operations at Alcon, Bausch+Lomb, and AstraZeneca. The brand names on the box (Systane, Refresh, Albuterol Sulfate, Simply Saline) are regulatory filing holders and marketers, not manufacturers. Unither physically produces products for multiple competing pharmaceutical brands from the same GMP-certified facility — meaning Novartis-branded and AbbVie-branded eye drops may be manufactured on the same Unither production line in Amiens, with different labels applied. Brand differentiation in unit-dose pharmaceutical liquids is increasingly a labeling exercise; the manufacturing oligopoly is nearly invisible to prescribers, pharmacists, and patients.
Unither Pharmaceuticals ↗Origin2024
Unither Pharmaceuticals was founded in 1993 in Amiens, northern France, as a pharmaceutical contract manufacturer specifically focused on blow-fill-seal (BFS) unit-dose production — a highly specialized choice at a time when most CMOs pursued diversified filling technologies. By betting entirely on BFS for sterile liquid unit-dose packaging, Unither accumulated deep BFS regulatory expertise and operational scale that generalist CMOs lacked. The strategic focus paid off: Unither became one of the largest independent BFS CDMOs globally, with multi-billion-ampoule annual capacity across facilities in France (Amiens, Gannat) and the US (Wilson, North Carolina). Bpifrance, the French public investment bank, has backed Unither — the French government treats BFS pharmaceutical manufacturing as a strategic sovereign capability after COVID exposed France's dependence on contract manufacturers for essential medicine supply.
Unither Pharmaceuticals ↗